Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Jonathan E. Campbell
Molecular Metabolism (2020) Vol. 46, pp. 101139-101139
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 250
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 221
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla Collins, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 152
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
Tito Borner, Caroline E. Geisler, Samantha M. Fortin, et al.
Diabetes (2021) Vol. 70, Iss. 11, pp. 2545-2553
Open Access | Times Cited: 109
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 105
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 84
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 82
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 65
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Manmeet Kaur, Saurav Misra
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 5, pp. 669-676
Closed Access | Times Cited: 32
A comprehensive spatio-cellular map of the human hypothalamus
John A. Tadross, Lukas Steuernagel, Georgina K.C. Dowsett, et al.
Nature (2025) Vol. 639, Iss. 8055, pp. 708-716
Open Access | Times Cited: 7
Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control
Paul El Meouchy, Mohamad Wahoud, Sabine Allam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12305-12305
Open Access | Times Cited: 69
Hindbrain circuits in the control of eating behaviour and energy balance
Wenwen Cheng, Desiree Gordian, Mette Q. Ludwig, et al.
Nature Metabolism (2022) Vol. 4, Iss. 7, pp. 826-835
Closed Access | Times Cited: 64
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 53
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Lyudmila Viktorovna Nedosugova, Yuliya V. Markina, Л. А. Бочкарева, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1168-1168
Open Access | Times Cited: 49
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 46
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Jonathan E. Campbell, Jacqueline L. Beaudry, Berit Svendsen, et al.
Diabetes (2022) Vol. 71, Iss. 5, pp. 1115-1127
Open Access | Times Cited: 42
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Yusman Manchanda, Stavroula Bitsi, Shiqian Chen, et al.
Endocrinology (2023) Vol. 164, Iss. 5
Open Access | Times Cited: 29
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 27
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1069-1084
Open Access | Times Cited: 14
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys
M. Jensen, Samra Joke Sanni, Ditte Riber, et al.
Molecular Metabolism (2024) Vol. 88, pp. 102006-102006
Open Access | Times Cited: 11
Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose–High-Lipid Conditions: A Comparative Study
Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 421-421
Open Access | Times Cited: 1
On the causes of obesity and its treatment: The end of the beginning
Jeffrey M. Friedman
Cell Metabolism (2025) Vol. 37, Iss. 3, pp. 570-577
Open Access | Times Cited: 1
Injectables Pharmacotherapies for Obesity: Mechanisms, Efficacy, and Aesthetic Implications
José Melo Gomes, Alan Cristian Marinho Ferreira, Antony de Paula Barbosa
Obesities (2025) Vol. 5, Iss. 2, pp. 22-22
Open Access | Times Cited: 1
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Makoto Fukuda
Diabetes (2021) Vol. 70, Iss. 9, pp. 1929-1937
Open Access | Times Cited: 42
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top